$3M funding for plant-inspired halogenated small molecule drugs

Seed fund

Biomia, the first company spun out from BioInnovation Institute’s Bio Studio programme, has secured $3 million in pre-seed financing from an international syndicate of investors.

Biomia says it plans to use the investment to accelerate its development of plant-inspired natural and new-to-nature halogenated small molecule drug candidates and further build its biosynthetic manufacturing platform.

Chief Innovation Officer at BioInnovation Institute, Trine Bartholdy, said: “Biomia is at the forefront of innovation in the biosynthesis field. Through our Bio Studio programme, we are proud to have helped and guided the team with both scientific and commercial maturation to spin out a company and raise investment from an international syndicate of investors. This is an outstanding example of how we support platform technologies based on world-class science to become viable companies that can positively impact human and planetary health.”

The company has developed a pipeline of monoterpenoid indole alkaloids (MIAs) for unmet medical needs in pain, addiction, and mental health conditions. It aims to generate improved drug candidates with optimised ADME properties and tox profiles by integrating halogenation into the design of new-to-nature MIA drug leads.

CEO of Biomia, Michael Krogh Jensen, commented: “We would like to thank the Novo Nordisk Foundation, The Novo Nordisk Foundation Center for Biosustainability at DTU, and BioInnovation Institute for their support. We also owe thanks to EU’s Framework Programme for Research and Innovation and our strategic collaborators from this programme. The successful conclusion of Biomia’s pre-seed financing marks a pivotal step forward in the company’s mission to design and develop groundbreaking plant-inspired new-to-nature small molecule drug candidates for patients with unmet needs.”

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free